Quick Answer
Polaryx Therapeutics, Inc. reported Cash and Equivalents of $5.14 million for fiscal year 2025.
Polaryx Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $5.14M | +11.3% |
| 2024 | $4.62M | — |
- Polaryx Therapeutics, Inc. showed an increase of +11.3% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2024–2025 period, Polaryx Therapeutics, Inc.’s cash and equivalents has grown by 11.3% (from $4.62 million to $5.14 million).
- The most recent figure is from Polaryx Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: